PharmaLex Group, a provider of specialised services for the pharma, biotech and medtech industries worldwide, has completed a merger with Oblikue Consulting.
Oblikue offers support to clients across all stages, from pre- to post-launch, and further assists health authorities in defining healthcare policies to create market access programs for the biotechnology industry.
Its clients include global pharmaceutical companies, as well as all major Spanish companies.
Through the merger, PharmaLex will gain critical scale to its emerging offering in the strategic growth area of pricing and reimbursement (P&R), opening up growth opportunities across the European market. In addition, Oblikue has experience in LATAM countries with projects in Brazil and Chile.
“Our shared commitment to quality and business pragmatism will benefit customers of both businesses,” commented Max Brosa, founder and general manager of Oblikue Consulting. “Together, we will help customers with all aspects of their market submission – from strategic planning to P&R submission, market access, and beyond.”
“The acquisition of Oblikue fits with our objective to strengthen our health economics and market access expertise and expand our reach in Spain,” said Dr Thomas Dobmeyer, CEO PharmaLex. “Oblikue is well-known for its P&R experience, as well as its skill at liaising between pharma customers and healthcare stakeholders and tailoring projects to customer’s needs. We are very pleased to welcome them to PharmaLex.”